These items were presented at the American College of Allergy, Asthma and Immunology annual meeting (ACAAI):
• Baxter International Inc., of Deerfield, Ill., presented Phase III data that showed patients with primary immunodeficiencies had a reduced rate of serious bacterial infections when treated with HyQ, an investigational combination immunoglobulin product. The data also suggested the possibility for a three- or four-week dosing schedule with single-site, self-administered infusions. The prospective, open-label study enrolled 89 patients in Canada and the U.S.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST